Table 3. Treatment response summary for anti-cancer activity of MPT0E028 and SAHA in the human HCT116 colorectal cancer xenograft model.
| Compound (n) | Dose (mg/kg) | Route | Schedule | Median TTE | T-C | %TGD | No. of CR | Logrank Significance | P value |
| Control (8) | – | po | qd to endpoint | 16.6 | – | – | 0 | ||
| SAHA (8) | 200 | po | qd to endpoint | 27.0 | 10 | 63% | 0 | * | 0.0251 |
| MPT0E028 (8) | 200 | po | qd to endpoint | 36.9 | 20 | 122% | 3 | ** | 0.0031 |
| MPT0E028 (8) | 100 | po | qd to endpoint | 19.2 | 2.6 | 16% | 1 | ns | 0.3084 |
| MPT0E028 (8) | 50 | po | qd to endpoint | 15.5 | – | – | 0 | ns | 0.7890 |
n = number of animals; Study Endpoint = 1200 mm3, Days in Progress = 60; TTE = time to endpoint; T-C = difference between median TTE (days) of treated versus control group; %TGD (tumor growth delay) = [(T-C)/C]×100; CR = complete regression; Statistical Significance = Logrank test; ns = not significant; * = P<0.05 compare with control. qd = once daily; po = oral administration.